<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title>Evan Albright — Digest tagged &quot;media&quot;</title><description>Digest issues tagged #media.</description><link>https://www.evanalbright.com/</link><language>en-us</language><item><title>OpenAI model cracks an 80-year-old math problem as Lilly&apos;s obesity drug hits surgery-level results</title><link>https://www.evanalbright.com/digest/2026-05-21/</link><guid isPermaLink="true">https://www.evanalbright.com/digest/2026-05-21/</guid><description>An OpenAI reasoning model disproved an 80-year-old Erdős conjecture in discrete geometry for under $1,000 in compute, a result mathematicians are calling one of the most significant AI contributions to pure math to date. Eli Lilly&apos;s retatrutide, a triple-receptor obesity drug, produced bariatric-surgery-level weight loss in a Phase 3 trial, though dropout rates from side effects were notable. Google shipped Gemini 3.5 Flash to general availability at Google I/O and announced a $100 AI Ultra subscription tier. The acting head of NIH&apos;s infectious disease institute stepped down as senators pressed NIH Director Jay Bhattacharya on leadership gaps and a proposed 2027 budget cut. Kevin Warsh was confirmed and sworn in as the new Federal Reserve chair this week.</description><pubDate>Thu, 21 May 2026 00:00:00 GMT</pubDate><category>ai</category><category>pharma</category><category>economy</category><category>healthtech</category><category>software</category><category>llm</category><category>obesity</category><category>fed</category><category>nih</category><category>openai</category><category>google</category><category>gemini</category><category>mathematics</category><category>agents</category><category>clinical-trials</category><category>reasoning</category><category>evals</category><category>inference</category><category>models</category><category>products</category><category>ide</category><category>developer-tools</category><category>antigravity</category><category>datasette</category><category>open-source</category><category>python</category><category>spacex</category><category>infrastructure</category><category>training</category><category>compute</category><category>codex</category><category>engineering</category><category>gpt</category><category>productivity</category><category>workflow</category><category>tools</category><category>anthropic</category><category>cloud</category><category>security</category><category>enterprise</category><category>education</category><category>deployment</category><category>strategy</category><category>rag</category><category>embedding</category><category>retrieval</category><category>grok</category><category>nvidia</category><category>efficiency</category><category>ux</category><category>policy</category><category>access</category><category>partnership</category><category>compliance</category><category>safety</category><category>verification</category><category>synthetic-media</category><category>meta</category><category>layoffs</category><category>rust</category><category>systems</category><category>android</category><category>survey</category><category>language</category><category>macos</category><category>text-editor</category><category>agent</category><category>database</category><category>sandbox</category><category>visualization</category><category>model</category><category>tool</category><category>cost-tracking</category><category>design</category><category>glp-1</category><category>lilly</category><category>phase3</category><category>adc</category><category>oncology</category><category>lung-cancer</category><category>merck</category><category>niaid</category><category>leadership</category><category>public-health</category><category>senate</category><category>budget</category><category>medicare</category><category>fraud</category><category>insurance</category><category>doj</category><category>clinical-trial</category><category>biotech</category><category>geopolitics</category><category>pediatric</category><category>immunology</category><category>market</category><category>fda</category><category>wearable</category><category>media</category><category>publishing</category><category>ehr</category><category>privacy</category><category>surveillance</category><category>clinical</category><category>workforce</category><category>surgery</category><category>burnout</category><category>health-policy</category><category>wearables</category><category>blood-pressure</category><category>digital-health</category><category>regulation</category><category>pancreatic-cancer</category><category>kras</category><category>asco</category><category>telehealth</category><category>uspstf</category><category>monetary-policy</category><category>interest-rates</category><category>macro</category><category>capex</category><category>tech</category><category>investment</category><category>payments</category><category>fintech</category><category>research</category><category>labor</category><category>unions</category><category>wages</category><category>finance</category><category>demographics</category><category>behavior</category><category>science</category><category>psychology</category><category>decision-making</category><category>economics</category><category>bonds</category><category>smartphones</category><category>fertility</category><category>migration</category><category>remittances</category><category>developing-economies</category><category>space</category><category>innovation</category><category>markets</category></item><item><title>Raschka and Willison close out 2025 with competing LLM retrospectives as NIH signals DEI grants will lapse</title><link>https://www.evanalbright.com/digest/2026-01-01/</link><guid isPermaLink="true">https://www.evanalbright.com/digest/2026-01-01/</guid><description>Sebastian Raschka published a comprehensive 2025 LLM review covering DeepSeek R1, RLVR, inference-time scaling, and 2026 predictions, while Simon Willison released his annual year-in-LLMs retrospective. On the pharma front, NIH Director Jay Bhattacharya confirmed that DEI-related grants restored under a court order will not be renewed in 2026, even as NIH began reviewing thousands of delayed proposals and funded 135 on the first day. Novo Nordisk priced its newly approved Wegovy pill below Eli Lilly&apos;s competing obesity drug in a direct-to-consumer push. On the economy side, researchers across 16 countries found that the post-1980 labor share decline is driven by the composition of capital, not its quantity, and building more structures may reverse it.</description><pubDate>Thu, 01 Jan 2026 00:00:00 GMT</pubDate><category>ai</category><category>software</category><category>pharma</category><category>healthtech</category><category>economy</category><category>llm</category><category>nih</category><category>housing</category><category>labor</category><category>obesity</category><category>inference</category><category>benchmarks</category><category>policy</category><category>research</category><category>rlvr</category><category>evals</category><category>papers</category><category>training</category><category>open-source</category><category>rl</category><category>architecture</category><category>ai-safety</category><category>video-generation</category><category>openai</category><category>models</category><category>multimodal</category><category>productivity</category><category>coding</category><category>reasoning</category><category>product</category><category>naming</category><category>programming</category><category>tools</category><category>web-scraping</category><category>cli</category><category>cognition</category><category>sqlite</category><category>governance</category><category>web</category><category>engineering</category><category>archiving</category><category>testing</category><category>version-control</category><category>funding</category><category>grants</category><category>pricing</category><category>biopharma</category><category>rare-disease</category><category>access</category><category>fda</category><category>clinical-trials</category><category>clinical</category><category>opinion</category><category>dei</category><category>medicine</category><category>healthcare</category><category>litigation</category><category>healthcare-policy</category><category>aca</category><category>drug-pricing</category><category>photojournalism</category><category>education</category><category>doctors</category><category>novo-nordisk</category><category>rural-health</category><category>cms</category><category>health-policy</category><category>pbm</category><category>government</category><category>public-health</category><category>alcohol</category><category>evidence</category><category>capital</category><category>inequality</category><category>inventory</category><category>gen-z</category><category>gdp</category><category>growth</category><category>tariffs</category><category>china</category><category>technology</category><category>risk</category><category>finance</category><category>markets</category><category>prediction</category><category>media</category><category>accountability</category><category>us-economy</category><category>quality-of-life</category><category>culture</category><category>music</category><category>social-media</category><category>art</category><category>podcast</category><category>economics</category><category>politics</category><category>analysis</category><category>history</category><category>trade</category><category>infrastructure</category></item></channel></rss>